Woodline Partners LP Esperion Therapeutics, Inc. Transaction History
Woodline Partners LP
- $10.5 Billion
- Q1 2024
A detailed history of Woodline Partners LP transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 7,922,229 shares of ESPR stock, worth $17.6 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
7,922,229
Previous 290,382
2628.21%
Holding current value
$17.6 Million
Previous $868,000
2345.97%
% of portfolio
0.2%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding ESPR
# of Institutions
174Shares Held
125MCall Options Held
2.08MPut Options Held
1.01M-
Orbimed Advisors LLC San Diego, CA13.7MShares$30.4 Million0.83% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$22.1 Million0.42% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.13MShares$20.3 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.83MShares$19.6 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT8MShares$17.8 Million5.25% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $148M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...